Copyright
©2013 Baishideng Publishing Group Co.
World J Gastrointest Endosc. Apr 16, 2013; 5(4): 180-185
Published online Apr 16, 2013. doi: 10.4253/wjge.v5.i4.180
Published online Apr 16, 2013. doi: 10.4253/wjge.v5.i4.180
Table 1 Medications associated with ischemic colitis
| Agent | Mechanism |
| Amphetamines | Vasoconstriction |
| Alosetron | |
| Catecholamines (epinephrine, norepinephrine) | |
| Cocaine | |
| Cyclosporine | |
| Digitalis | |
| Dopamine | |
| Ergot derivatives | |
| Nonsteriodal anti-inflammatory drugs | |
| Pseudoephedrine | |
| Triptans (Naratriptan, Rizatriptan, Sumatriptan) | |
| Vasopressin and vasopressin analogues | |
| Glycerin enema | Local vasospasm effect |
| Phosphosoda solution | |
| Angiotensin-converting enzyme inhibitors | Systemic hypotension |
| Antipsychotic (chlorpromazine) | |
| Beta blockers | |
| Barbiturates | |
| Diuretics | |
| Interleukin-2 | |
| Tricyclic antidepressants | |
| Amphetamines | Vasculitis |
| Gold compounds | |
| Estrogens | Thrombotic lesion induction |
| Progestational agents | |
| Alosetron | Increased intracolic pressure |
| Danazol | |
| Glycerin enema | |
| Carboplatin | Undetermined |
| Flutamide | |
| Glutaraldehyde | |
| Hyperosmotic saline laxatives | |
| Interferon-α | |
| Mycophenolate mofetil | |
| Paclitaxel | |
| Simvastatin | |
| Tegaserod |
Table 2 Naranjo adverse drug reaction nomogram in our patient
| Yes | No | Our patient | |
| 1: Are there previous conclusive reports on this reaction? | 1 | 0 | 0 |
| 2: Did the adverse event appear after the suspected drug was administered? | 2 | -1 | 2 |
| 3: Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? | 1 | 0 | 1 |
| 4: Did the adverse reaction reappear when the drug was readministered? | 2 | -1 | 0 |
| 5: Are there alternative causes (other than the drug) that could have, on their own, caused the reaction? | -1 | 2 | 2 |
| 6: Did the reaction appear when a placebo was given? | -1 | 1 | 1 |
| 7: Was the drug detected in the blood (or other fluids) in concentration known to be toxic? | 1 | 0 | 0 |
| 8: Was the reaction more severe when the dose was increased or less severe when dose was decreased? | 1 | 0 | 0 |
| 9: Did the patient have a similar reaction to the same or similar drugs in any previous exposure? | 1 | 0 | 0 |
| 10: Was the adverse event confirmed by any objective evidence? | 1 | 0 | 1 |
- Citation: Sherid M, Samo S, Sulaiman S, Gaziano JH. Ischemic colitis induced by the newly reformulated multicomponent weight-loss supplement Hydroxycut®. World J Gastrointest Endosc 2013; 5(4): 180-185
- URL: https://www.wjgnet.com/1948-5190/full/v5/i4/180.htm
- DOI: https://dx.doi.org/10.4253/wjge.v5.i4.180
